Pacira BioSciences stock falls 2.35 percent to USD 24.11

Pacira BioSciences, Inc. (ISIN US6951271005) closed at USD 24.11 on Nasdaq on September 21, 2026, down 2.35 percent from the previous close. The decline came as the wider Nasdaq Composite gained 2.26 percent during the same session, leaving Pacira behind the index by 4.61 percentage points.

Stock trails the broader market

The closing price placed Pacira at a market capitalization of USD 961.07 million on September 21, 2026. A separate market-capitalization record showed USD 0.98 billion for September 14, 2026, indicating that the company's equity value remained close to the USD 1 billion threshold during the period.

The market data identify Pacira as a specialty and generic drug manufacturer. Its PCRX ticker and Nasdaq listing provide the primary reference for the stock, so the USD 24.11 close is not mixed with secondary European quotations.

Operating figures need a dated update

The available market snapshot names Pacira BioSciences and reports trailing revenue of USD 1.67 billion, but it does not attach that figure to a clearly identified quarter, half-year or fiscal year. It is therefore not presented as a current reporting-period result.

The clearest quantified comparison is market-based: PCRX fell 2.35 percent on September 21, 2026, while the Nasdaq Composite rose 2.26 percent. That 4.61 percentage point gap shows that Pacira underperformed the main US technology index even as the broader market advanced.

Nasdaq close sets the reference

Pacira BioSciences closed at USD 24.11 on Nasdaq on September 21, 2026. The same market snapshot reported a 52-week range and trading volume for another security rather than a verified PCRX range and volume, so those values are not included here.

More news and analyses on Pacira BioSciences stock